NCT01449682 - Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

February 28, 2013

Conditions

Retinal Vein OcclusionMacular Edema

Interventions

DRUG

Ozurdex

0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies

DRUG

Ozurdex

0.7 mg intravitreal DEX implant on first visit then every 16 weeks

Trial Locations (1)

Retina Macula Institute, Torrance